AP2814A - 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands - Google Patents

1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands

Info

Publication number
AP2814A
AP2814A AP2011005664A AP2011005664A AP2814A AP 2814 A AP2814 A AP 2814A AP 2011005664 A AP2011005664 A AP 2011005664A AP 2011005664 A AP2011005664 A AP 2011005664A AP 2814 A AP2814 A AP 2814A
Authority
AP
ARIPO
Prior art keywords
hydroxytryptamine
benzimidazoles
arylsulfonyl
piperazin
ligands
Prior art date
Application number
AP2011005664A
Other languages
English (en)
Other versions
AP2011005664A0 (en
Inventor
Patrick M Andrae
Simon N Haydar
Albert J Robichaud
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2814(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of AP2011005664A0 publication Critical patent/AP2011005664A0/xx
Application granted granted Critical
Publication of AP2814A publication Critical patent/AP2814A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2011005664A 2008-11-11 2009-11-10 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands AP2814A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11
PCT/US2009/063816 WO2010056644A1 (en) 2008-11-11 2009-11-10 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS

Publications (2)

Publication Number Publication Date
AP2011005664A0 AP2011005664A0 (en) 2011-04-30
AP2814A true AP2814A (en) 2013-12-31

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005664A AP2814A (en) 2008-11-11 2009-11-10 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands

Country Status (41)

Country Link
US (1) US8063053B2 (en:Method)
EP (1) EP2285784B1 (en:Method)
JP (1) JP5087171B2 (en:Method)
KR (1) KR101323417B1 (en:Method)
CN (1) CN102209713B (en:Method)
AP (1) AP2814A (en:Method)
AR (1) AR074325A1 (en:Method)
AU (1) AU2009314221B2 (en:Method)
BR (1) BRPI0920682A2 (en:Method)
CA (1) CA2740262C (en:Method)
CL (1) CL2011001050A1 (en:Method)
CO (1) CO6440548A2 (en:Method)
CR (1) CR20110247A (en:Method)
CU (1) CU24020B1 (en:Method)
CY (1) CY1113025T1 (en:Method)
DK (1) DK2285784T3 (en:Method)
DO (1) DOP2011000130A (en:Method)
EA (1) EA018369B1 (en:Method)
EC (1) ECSP11011045A (en:Method)
ES (1) ES2389694T3 (en:Method)
GE (1) GEP20135805B (en:Method)
HR (1) HRP20120561T1 (en:Method)
IL (1) IL212213A0 (en:Method)
MA (1) MA32788B1 (en:Method)
ME (1) ME01129B (en:Method)
MX (1) MX2011004996A (en:Method)
MY (1) MY156324A (en:Method)
NI (1) NI201100093A (en:Method)
NZ (1) NZ592563A (en:Method)
PE (1) PE20120026A1 (en:Method)
PL (1) PL2285784T3 (en:Method)
PT (1) PT2285784E (en:Method)
RS (1) RS52381B (en:Method)
SA (1) SA109300673B1 (en:Method)
SI (1) SI2285784T1 (en:Method)
SV (1) SV2011003902A (en:Method)
TN (1) TN2011000203A1 (en:Method)
TW (1) TWI481605B (en:Method)
UA (1) UA100192C2 (en:Method)
WO (1) WO2010056644A1 (en:Method)
ZA (1) ZA201103283B (en:Method)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005286728A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1804792A1 (en) * 2004-09-20 2007-07-11 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
CA2580857A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286648A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
WO2021021951A1 (en) 2019-07-29 2021-02-04 Vanderbilt University Wdr5-myc inhibitors
EP4121413A4 (en) * 2020-04-22 2024-04-17 Recurium IP Holdings, LLC PREPARATION OF A SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036562A2 (en) * 2000-11-02 2002-05-10 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US20020165251A1 (en) * 2000-10-20 2002-11-07 Patrizia Caldirola Novel compounds, their use and preparation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
WO1999002502A2 (en) 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
PT930302E (pt) 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
ES2192394T3 (es) 1998-08-10 2003-10-01 Winston Pharmateuticals Llc Profarmacos de inhibidores de la bomba de protones.
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
CA2450245A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
CA2502356A1 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
US7745436B2 (en) 2004-04-13 2010-06-29 Synta Pharmaceuticals Corporation Disalt inhibitors of IL-12 production
EP1778242A4 (en) 2004-07-28 2010-10-20 Irm Llc COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDHORMONE NUCLEAR RECEPTORS
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165251A1 (en) * 2000-10-20 2002-11-07 Patrizia Caldirola Novel compounds, their use and preparation
WO2002036562A2 (en) * 2000-11-02 2002-05-10 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAHMOOD AHMED ET AL.: "Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists". BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, no. 21, 2005, pages 4867-4871 *

Also Published As

Publication number Publication date
ES2389694T3 (es) 2012-10-30
JP2012508275A (ja) 2012-04-05
AU2009314221B2 (en) 2012-08-30
AU2009314221A1 (en) 2010-05-20
PE20120026A1 (es) 2012-02-12
DOP2011000130A (es) 2017-04-30
CY1113025T1 (el) 2016-04-13
NZ592563A (en) 2012-10-26
MY156324A (en) 2016-02-15
EP2285784A1 (en) 2011-02-23
NI201100093A (es) 2011-10-31
TN2011000203A1 (fr) 2012-12-17
CN102209713A (zh) 2011-10-05
EA201100696A1 (ru) 2011-10-31
TW201022247A (en) 2010-06-16
TWI481605B (zh) 2015-04-21
CA2740262C (en) 2013-05-28
HRP20120561T1 (hr) 2012-07-31
AR074325A1 (es) 2011-01-05
ZA201103283B (en) 2012-01-25
CL2011001050A1 (es) 2011-08-19
IL212213A0 (en) 2011-06-30
PL2285784T3 (pl) 2012-12-31
MX2011004996A (es) 2011-05-25
ECSP11011045A (es) 2011-06-30
GEP20135805B (en) 2013-04-10
US8063053B2 (en) 2011-11-22
JP5087171B2 (ja) 2012-11-28
SA109300673B1 (ar) 2013-05-25
EP2285784B1 (en) 2012-07-04
DK2285784T3 (da) 2012-07-23
CA2740262A1 (en) 2010-05-20
MA32788B1 (fr) 2011-11-01
PT2285784E (pt) 2012-09-19
ME01129B (me) 2013-03-20
RS52381B (sr) 2012-12-31
WO2010056644A8 (en) 2010-11-18
HK1158647A1 (en) 2012-07-20
SV2011003902A (es) 2011-07-05
US20100120779A1 (en) 2010-05-13
BRPI0920682A2 (pt) 2016-09-27
UA100192C2 (en) 2012-11-26
CO6440548A2 (es) 2012-05-15
AP2011005664A0 (en) 2011-04-30
EA018369B1 (ru) 2013-07-30
SI2285784T1 (sl) 2012-08-31
KR20110075013A (ko) 2011-07-05
CN102209713B (zh) 2014-07-02
CU24020B1 (es) 2014-07-30
CU20110101A7 (es) 2012-01-31
KR101323417B1 (ko) 2013-10-29
WO2010056644A1 (en) 2010-05-20
CR20110247A (es) 2011-06-24

Similar Documents

Publication Publication Date Title
ZA201103283B (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
ZA200908624B (en) 5-heteroaryl substituted indazoles as kinase inhibitors
PL4218732T3 (pl) Tabletki zawierające eltrombopag z olaminą
IL209729A0 (en) Novel phenylpyrazinones as kinase inhibitors
IL209122A0 (en) Phenyl or pyridinyl substituted indazoles derivatives
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
SI2364137T1 (sl) Farmacevtska suspenzija
IL207225A0 (en) Indazole derivatives
IL202666A0 (en) Substituted piperazines
IL212571A0 (en) Aryl piperazine and their use as alpha2c antagonists
IL209733A0 (en) New benzimidazole derivatives
ZA200904920B (en) Benzimidazole TRPV1 inhibitors
IL211806A0 (en) New benzimidazole derivatives
ZA201105219B (en) (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
EP2345644A4 (en) INDAZOLE COMPOUND
IL194365A0 (en) Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
PH32008000364S1 (en) Cross connect block